MAPT and Alzheimer disease: Interestingly, U1 snRNP components already aggregate in asymptomatic AD cases, i.e., in the brains of patients with Aβ deposition in the absence of tau deposition and cognitive impairment [88], reinforcing the idea that RBP alterations may be linked to the development of AD.